Filing Details
- Accession Number:
- 0001104659-24-030156
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2024-03-01 20:45:27
- Reporting Period:
- 2024-02-29
- Accepted Time:
- 2024-03-01 20:45:27
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
1377121 | Protagonist Therapeutics Inc | PTGX | Pharmaceutical Preparations (2834) | 980505495 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1921163 | Asif Ali | C/O Protagonist Therapeutics, Inc. 7707 Gateway Blvd., Suite 140 Newark CA 94560-1160 | Chief Financial Officer | No | Yes | No | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Common Stock | Disposition | 2024-02-29 | 7,850 | $30.61 | 42,734 | No | 4 | S | Direct | |
Common Stock | Disposition | 2024-02-29 | 2,089 | $31.00 | 40,645 | No | 4 | S | Direct | |
Common Stock | Acquisiton | 2024-03-01 | 12,000 | $12.17 | 52,645 | No | 4 | M | Direct | |
Common Stock | Disposition | 2024-03-01 | 12,000 | $32.22 | 40,645 | No | 4 | S | Direct | |
Common Stock | Disposition | 2024-03-01 | 2,248 | $32.33 | 38,397 | No | 4 | S | Direct |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | S | Direct | |
No | 4 | S | Direct | |
No | 4 | M | Direct | |
No | 4 | S | Direct | |
No | 4 | S | Direct |
Reported Derivative Transactions
Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
---|---|---|---|---|---|---|---|
Common Stock | Stock Option (right to buy) | Disposition | 2024-03-01 | 12,000 | $0.00 | 12,000 | $12.17 |
Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
---|---|---|---|---|---|---|
51,750 | 2033-01-15 | No | 4 | M | Direct |
Footnotes
- The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $30.57 to $30.76. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
- The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $32.17 to $32.31. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
- The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $32.28 to $32.39. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
- The stock option was granted to the Reporting Person on January 16, 2023 and vests in 48 equal monthly installments following the date of grant.